Riskpilot← Back to searchSign inGet full accessEmedic AB
ABActiveOrg 5590256821Nygårdavägen 111Painting and glazing · NACE 4334Est. 20150 employees
Revenue 2024
SEK 1,1M
+59% vs 2023
EBITDA margin
25.5%
+140% vs 2023
Equity ratio
44.8%
Financial strength
Net profit 2024
SEK 162K
+30% vs 2023
| Revenue | SEK 1,1M | +59% |
| EBITDA | SEK 273K | +140% |
| Net profit | SEK 162K | +30% |
| Total assets | SEK 488K | +54% |
| Equity | SEK 219K | +6% |
| Employees | 0 | — |
Legal name
Emedic AB
Org number
5590256821
Legal form
Aktiebolag
NACE code
4334 · Painting and glazing
Founded
8 september 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva försäljning och marknadsföring av tandblekningsprodukter, medicinsk utrustning och därmed förenlig verksamhet.
Address
Nygårdavägen 111
Email
kontakt@emedic.nu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 638 | 1 159 | 1 144 | 672 | 1 070 |
| Staff expenses | — | — | −117 | −184 | −232 |
| EBITDA | 149 | 381 | 314 | 114 | 273 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 149 | 381 | 314 | 114 | 273 |
| Net financials | −1 | −4 | −3 | −4 | 1 |
| Profit before tax | 148 | 377 | 232 | 160 | 205 |
| Tax | −32 | −79 | −49 | −35 | −43 |
| Net profit | 116 | 298 | 183 | 125 | 162 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 443 | 944 | 995 | 317 | 488 |
| Equity | 180 | 479 | 262 | 207 | 219 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 263 | 465 | 655 | 81 | 171 |
| Total debt | 263 | 465 | 655 | 81 | 171 |
EBITDA margin
25.5%
This company
15.8%
Market median
+61% vs market
20202024
Equity ratio
44.8%
This company
38.2%
Market median
+17% vs market
20202024
Return on equity
74.1%
This company
18.4%
Market median
+303% vs market
20202024
Net profit margin
15.1%
This company
8.1%
Market median
+86% vs market
20202024
Asset turnover
2.19×
This company
1.12×
Market median
+96% vs market
20202024
Debt / equity
1.23×
This company
0.62×
Market median
-98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CJ Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Emedic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cristopher Jonathan Michael Holmquist | Chief Executive Officer | 0 companies |
| Zoe Airi Book | Deputy Board Member | 0 companies |
| Lena Cassandra Marie L Holmquist | Deputy Board Member | 0 companies |